Special Issue

Cytokine-Induced Killer (CIK) Cells

Message from the Guest Editor

Dear Colleagues,

This Special Issue, “Cytokine-Induced Killer (CIK) Cells”, will cover a selection of recent research topics and current review articles in this field. Experimental papers, up-to-date review articles and commentaries are all welcome.

Cytokine-induced killer (CIK) cells represent an exceptional lymphocyte population uniting a T cell and natural killer cell like phenotype with non-MHC-restricted tumor-killing activity. CIK cells are expandable from peripheral blood mononuclear cells or cord blood and mature following the addition of certain cytokines and an antibody against CD3. CIK cells have provided encouraging results in in vitro and in clinical studies and revealed synergistic antitumor effects when combined with standard therapeutic procedures. Interestingly, exciting novel in vitro improvements of CIK cells have been reported.

CIK cells are licensed, e.g., in Germany. Due to their easy availability and potent antitumor activity, CIK cells emerged as a promising immunotherapy approach in oncology and may gain major importance in the prognosis of cancer.

Prof. Dr. Ingo Schmidt-Wolf
Guest Editor

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed) and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 22 days after submission; acceptance to publication is undertaken in 8 days (median values for 2016).